Johnson & Johnson (JNJ) Surpasses Q2 Earnings and Revenue Estimates

Core Insights - Johnson & Johnson (JNJ) reported quarterly earnings of $2.77 per share, exceeding the Zacks Consensus Estimate of $2.66 per share, but down from $2.82 per share a year ago, representing an earnings surprise of +4.14% [1] - The company achieved revenues of $23.74 billion for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 4.13% and up from $22.45 billion year-over-year [2] - Johnson & Johnson has consistently outperformed consensus EPS and revenue estimates over the last four quarters [2] Earnings Outlook - The sustainability of the stock's price movement will depend on management's commentary during the earnings call and future earnings expectations [3][4] - The current consensus EPS estimate for the upcoming quarter is $2.75 on revenues of $23.17 billion, and for the current fiscal year, it is $10.64 on revenues of $91.33 billion [7] Industry Context - The Large Cap Pharmaceuticals industry, to which Johnson & Johnson belongs, is currently ranked in the top 26% of over 250 Zacks industries, indicating a favorable outlook [8] - Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact stock performance [5][6]